Covid-19: Two doses of Pfizer shot give 95% protection
The analysis revealed that the Pfizer-BioNTech vaccine is highly effective against the virus for all people over the age of 16 years.
Two doses of the Pfizer-BioNTech vaccine provide more than 95 per cent protection against infection, hospitalisation, severe illness and death, including among the elderly, according to the first national-level observational assessment of its effectiveness in Israel, published in The Lancet, a reputed medical journal.
The peer-reviewed analysis, based on de-identified national data, also reveals for the first time the public health benefits of a national vaccination programme, which was found to be the key driver of a decline in Covid-19 infections in Israel, the journal reported on Wednesday.
It added that while the findings are encouraging, the authors stress that a number of challenges to controlling the pandemic remain. The duration of immunity —– both from infection and immunisation —— remains unknown, and it is possible that new, vaccine-resistant variants could emerge in the future.
Preliminary vaccine effectiveness (VE) estimates of one dose of the Pfizer-BioNTech vaccine — which was approved for emergency use in Israel in December 2020 — have been reported in the United Kingdom (UK), Denmark, Israel, and the United States.
VE estimates for two doses have also been carried out in a subset of the population in Israel.
However, until now, national-level VE estimates of two doses of the Pfizer-BioNTech vaccine — the only Covid-19 vaccine available in Israel during the study period of January 24 to April 3 – were not available for a range of key outcomes, including VE among the elderly.
Lead author, Sharon Alroy-Preis of the Israel Ministry of Health, said: “As the country with the highest proportion of its population vaccinated against Covid-19, Israel provides a unique real-world opportunity to determine the effectiveness of the vaccine and to observe wider effects of the vaccination programme on public health.”.
She added: “Until this point, no country in the world had described the national public health impact of a nationwide Covid-19 vaccination campaign. These insights are hugely important because, while there are still some considerable challenges to overcome, they offer real hope that Covid-19 vaccination will eventually enable us to control the pandemic.”
The authors used national pandemic surveillance data recorded by the Israel Ministry of Health to produce VE estimates of two doses of the vaccine against outcomes including infection, severe and critical hospitalisations, and deaths.
The analysis revealed that the Pfizer-BioNTech vaccine is highly effective against the virus for all people over the age of 16 years, providing 95.3 per cent protection against infection and 96.7 per cent protection against death seven days after the second dose.
Protection against symptomatic and asymptomatic infection was 97.0 per cent and 91.5 per cent, respectively.
The vaccine is also highly effective for preventing hospitalisations and severe illness, providing 97.2 per cent protection against hospitalisation overall and 97.5 per cent protection against severe and critical hospitalisation.
By 14 days after vaccination, protections conferred by a second dose increased to 96.5 per cent protection against infection, 98.0 per cent against hospitalisation, and 98.1 per cent against death, according to the study.
Modi and US Vice President Kamala Harris discuss efforts to improve... READ MORE
The government council approved the extension to combat Covid and... READ MORE
This is for the first time Abu Dhabi is permitting mixing of Covid-19 ... READ MORE
UK PM has warned that it could derail plans for lockdown restrictions ... READ MORE
Starting May 24, Bahrain had suspended the entry of travellers coming ... READ MORE
It was in 2003 when the UAE recognised homoepathy as an alternative... READ MORE
The Kingdom has limited this year’s Haj to its citizens and... READ MORE
The car could be seen slowly falling, front-forward, into the large,... READ MORE